-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27

Benzinga·06/11/2026 12:30:56
Listen to the news
Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $23 to $27.